XNAS
CLNNW
Market cap37mUSD
Jun 05, Last price
0.03USD
1D
-19.55%
1Q
-19.14%
IPO
-96.79%
Name
Clene Inc.
Chart & Performance
Profile
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|
2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
Income | ||||||||
Revenues | 342 -47.71% | 654 38.27% | 473 -34.58% | |||||
Cost of revenue | 33,435 | 41,194 | 48,882 | |||||
Unusual Expense (Income) | ||||||||
NOPBT | (33,093) | (40,540) | (48,409) | |||||
NOPBT Margin | ||||||||
Operating Taxes | (14,639) | |||||||
Tax Rate | ||||||||
NOPAT | (33,093) | (40,540) | (33,770) | |||||
Net income | (39,400) -20.41% | (49,504) 224.00% | (15,279) 56.87% | |||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 9,243 | 42,094 | 11,460 | |||||
BB yield | ||||||||
Debt | ||||||||
Debt current | 1,285 | 20,709 | 6,980 | |||||
Long-term debt | 24,616 | 17,561 | 30,997 | |||||
Deferred revenue | ||||||||
Other long-term liabilities | 6,345 | 1,566 | 2,555 | |||||
Net debt | 13,746 | 3,270 | 14,662 | |||||
Cash flow | ||||||||
Cash from operating activities | (21,326) | (30,171) | (39,011) | |||||
CAPEX | (15) | (330) | (5,179) | |||||
Cash from investing activities | 6,316 | (1,499) | (10,164) | |||||
Cash from financing activities | (1,529) | 42,163 | 17,249 | |||||
FCF | (30,784) | (38,731) | (40,588) | |||||
Balance | ||||||||
Cash | 12,155 | 35,000 | 23,315 | |||||
Long term investments | ||||||||
Excess cash | 12,138 | 34,967 | 23,291 | |||||
Stockholders' equity | (282,051) | (242,511) | (193,009) | |||||
Invested Capital | 300,382 | 290,231 | 230,625 | |||||
ROIC | ||||||||
ROCE | ||||||||
EV | ||||||||
Common stock shares outstanding | 6,954 | 5,247 | 65,205 | |||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | (31,448) | (38,835) | (47,390) | |||||
EV/EBITDA | ||||||||
Interest | 4,064 | 4,558 | 3,296 | |||||
Interest/NOPBT |